FDA Approves First Gene Therapy for Young Children with Sickle Cell Disease

Why it matters locally: While the FDA approval is national, access to specialized gene therapies like Casgevy for conditions such as sickle cell disease could pose logistical and accessibility challenges in Idaho, particularly for families in rural areas needing to travel for treatment.

---

The U.S. Food and Drug Administration (FDA) today announced a supplemental approval for Casgevy (exagamglogene autotemcel). This expanded approval permits the use of the gene therapy for patients aged two years and older. The therapy is indicated for individuals diagnosed with sickle cell disease (SCD) who experience recurrent vaso-occlusive crises (VOCs). Additionally, the approval covers patients with transfusion-dependent beta thalassemia (TDT).